Covalent aminofuropyridine enal inhibitor of TAK1 sustains target engagement in mice and slows lymphoma xenograft growth
- An amino-substituted furo[2,3-c]pyridine scaffold was equipped with an enal warhead, yielding an irreversible, covalent TAK1 inhibitor (compound 26).
- In cells it blocked TAK1-driven signaling, and in mice it maintained target inhibition over time.
- It curbed growth of lymphoma xenografts, though off-target kinase contributions are possible; selectivity and pharmacokinetics still need optimization.
💡 Points Based on the abstract
An enal instead of the usual acrylamide is a deliberate choice: a more reactive but tunable electrophile aimed at a cysteine in TAK1's ATP pocket, the same logic as 5Z-7-oxozeaenol. A furopyridine hinge binder is a fresh alternative to that resorcylic lactone natural product. Sustained in vivo engagement is encouraging; until a kinome scan rules out off-target hits, I wouldn't credit the xenograft effect to TAK1.